Fused tricyclic benzimidazoles derivatives as modulators of TNF activity

A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being p...

Full description

Saved in:
Bibliographic Details
Main Authors Deligny Michael, Jackson Victoria Elizabeth, Selby Matthew Duncan, Keyaerts Jean, Durieu Veronique, Alexander Rikki Peter, Heer Jag Paul, Kroeplien Boris, Sabnis Yogesh Anil, Calmiano Mark Daniel, Heinelt Uwe, Swinnen Dominique Louis Leon, Van Houtvin Nathalie, Wehner Volkmar, Mac Coss Malcolm, Defays Sabine, Zhu Zhaoning
Format Patent
LanguageEnglish
Published 03.04.2018
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Bibliography:Application Number: US201415102003